S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine

Cancer Research

Volumn 61, Issue 3, 2001, Pages 1065-1072

  Shi, Z ^a   Azuma, A ^a   Sampath, D ^a   Li, Y X ^a   Huang, P ^a   Plunkett, W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; GEMCITABINE; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL;

ALKALOIDS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; S PHASE; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0035116697     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. New antimetabolites in cancer chemotherapy and their clinical impact
2. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer
3. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity
4. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
5. Conrrelation of cytotoxicity with incorporation of ara-C into DNA
6. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells
7. The ribonucleoside diphosphate reductase inhibitor (E)-2′-deoxy-(fluoromethylene)cytidine as a cytotoxic radiosensitizer in vitro
8. Biology of cell killing by 1-β-D-arabinofuranosylcytosine and its relevance to molecular mechanisms of cytotoxicity
9. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
10. Treatment of refractory AML
11. 1-β-D-arabinofuranosylcytosine in the treatment of acute myeloid leukemia: The role and place of high-dose regimens
12. High dose 1-β-D-arabinofuranosylcytosine (HDARAC) in refractory acute leukemia
13. Poor prognosis acute myelogenous leukemia
14. Prediction of response to chemotherapy in acute myelocytic leukemia
15. Treatment of resistant disease
16. 1-β-D-arabinofuranosylcytosine deamination in human leukaemic myeloblasts and resistance to 1-β-D-arabinofuranosylcytosine therapy
17. Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia
18. Multidrug resistance in acute myeloid leukaemia
19. Cytidine deaminase and the development of resistance to 1-β-D-arabinofuranosylcytosine
20. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents
21. Thymidine as a kinetic and biochemical modulator of 1-β-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia
22. The proliferative activity of leukaemic myeloblasts following the intravenous infusion of cytarabine
23. Cell kinetics after high dose 1-β-D-arabinofuranosylcytosine in patients with acute myelocytic leukemia
24. Cytokinetic changes after 1-β-D-arabinofuranosylcytosine in acute nonlymphocyte leukemia
25. Cell kinetic responses in childhood acute nonlymphocytic leukemia during high-dose therapy with 1-β-D-arabinofuranosylcytosine
26. S1-phase cells of the leukemic cell cycle sensitive to 1-β-D-arabinofuranosylcytosine at a high-dose level
27. Cell cycle checkpoints
28. DNA damage checkpoints: Implications for cancer therapy
29. Mammalian G1 and G2 phase checkpoints
30. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells
31. Chromosomes with two intact axial cores are induced by G2 checkpoint override: Evidence that DNA decatenation is not required to template the chromosome structure
32. Increased expression of cyclin B1 mRNA coincides with diminished G2-phase arrest in irradiated HeLa cells treated with staurosporine or caffeine
33. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
34. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity
35. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function
36. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines
37. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
38. Combined effect of CDDP and caffeine against human gastric cell line in vivo
39. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines
40. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
41. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α-1-acid glycoprutein in humans
42. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
43. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in mufine and human tumor models
44. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
45. The radiosensitizing agent 7-hydroxystaurnsporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
46. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
47. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
48. 7-Hydruxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells
49. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
50. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes
51. 2+ in radiation-induced apoptosis suppresses DNA fragmentation but does not enhance clonogenic survival
52. Cell cycle control and cancer
53. Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia
54. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: A leukemia intergroup study
55. Biochemical modulation of 1-β-D-arabinofuranosylcytosine
56. Ara-C: Cellular and molecular pharmacology
57. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases
58. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15
59. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle
60. Cdc25 inhibited in vivo and in vitro by checkpoint kinases Cds1 and Chk1
61. Chkl is a weel kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
62. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage
63. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
64. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
65. Association of Chk1 with 14-3-3 proteins is stimulated by DNA damage
66. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25
67. Replication checkpoint enforced by kinases Cds1 and Chk1
68. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1
69. Mechanisms of S-phase arrest induced by fludarabine and their modulation by the kinase inhibitor, UCN-01
70. The role of c-jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage
71. Interleukin3-induced phosphorylation of BAD through the protein kinase Akt
72. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase
73. The P1 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
74. Inhibition of the PI 3-kinase/Akt-BAD survival pathway by UCN-01 is associated with abrogation of gemcitabine-induced S phase arrest and induction of apoptosis